RRM2 Antibody [L9E5]

Catalog No.: F7845

Application: Reactivity: Human

Lane 1: HDLM-2, Lane 2: PANC-1, Lane 3: THP-1

当該製品は品切れ状态で、ごメールアドレスを教えていただければ、在庫があると、メールで顧客様に伝えます。

代表番号: 045-509-1970|電子メール：sales@selleck.co.jp

使用情報

Dilution
WB1:1000 IHC1:100-1:400 IF1:400-1:1600

Application
WB, IHC, IF

Source
Rabbit Monoclonal Antibody

Reactivity
Human

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW
45 kDa

Datasheet & SDS

生物学的記述

Specificity
RRM2 Antibody [L9E5] detects endogenous levels of total RRM2 protein.

Clone
L9E5

Synonym(s)
Ribonucleoside-diphosphate reductase subunit M2; RRM2

Background
Ribonucleotide reductase small subunit M2 (RRM2) is a catalytic subunit of the ribonucleotide reductase heterodimer that governs the rate‑limiting step in the conversion of ribonucleotides to deoxyribonucleotides and thereby sets the size and composition of cellular dNTP pools required for DNA replication and repair. RRM2 contains a di‑iron centre and radical‑transfer pathway that drives the reduction of ribonucleotide diphosphates, and its activity is tightly coupled to the larger RRM1‑containing holoenzyme whose assembly and redox state tune RRM2‑dependent dNTP production across the cell cycle. RRM2 expression peaks in S phase and G2, and CDK‑mediated phosphorylation of RRM2 at Thr33 during G2 targets the subunit to the SCF–Cyclin F ubiquitin ligase for proteasomal degradation, thereby coupling cell‑cycle progression to RRM2 turnover and preventing dNTP pool imbalance and genome instability. RRM2 is overexpressed and supports sustained proliferation, migration, and chemoresistance by maintaining elevated dNTP levels and concurrently engaging pro‑survival and signaling pathways such as Bcl‑2–dependent apoptosis control and RRM2‑linked Wnt/β‑catenin or JAK2/STAT3 signaling, while depletion or pharmacological inhibition of RRM2 impairs tumor growth, enhances sensitivity to DNA‑damaging agents and targeted kinase inhibitors, and delays relapse in models of BRAF‑mutant melanoma and chemoresistant carcinomas.

Background

Ribonucleotide reductase small subunit M2 (RRM2) is a catalytic subunit of the ribonucleotide reductase heterodimer that governs the rate‑limiting step in the conversion of ribonucleotides to deoxyribonucleotides and thereby sets the size and composition of cellular dNTP pools required for DNA replication and repair. RRM2 contains a di‑iron centre and radical‑transfer pathway that drives the reduction of ribonucleotide diphosphates, and its activity is tightly coupled to the larger RRM1‑containing holoenzyme whose assembly and redox state tune RRM2‑dependent dNTP production across the cell cycle. RRM2 expression peaks in S phase and G2, and CDK‑mediated phosphorylation of RRM2 at Thr33 during G2 targets the subunit to the SCF–Cyclin F ubiquitin ligase for proteasomal degradation, thereby coupling cell‑cycle progression to RRM2 turnover and preventing dNTP pool imbalance and genome instability. RRM2 is overexpressed and supports sustained proliferation, migration, and chemoresistance by maintaining elevated dNTP levels and concurrently engaging pro‑survival and signaling pathways such as Bcl‑2–dependent apoptosis control and RRM2‑linked Wnt/β‑catenin or JAK2/STAT3 signaling, while depletion or pharmacological inhibition of RRM2 impairs tumor growth, enhances sensitivity to DNA‑damaging agents and targeted kinase inhibitors, and delays relapse in models of BRAF‑mutant melanoma and chemoresistant carcinomas.

References
[1] D'Angiolella V, et al. Cell. 2012 May 25;149(5):1023-34. [2] Chen G, et al. Nat Commun. 2019 Jul 19;10(1):3213.

PVDFメンブレン孔径参考表

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須

* 大学・企業名 大学・企業名を記入してください

* 名前 名前を記入してください

* 電子メール 電子メール・アドレスを記入してください 有効なメールアドレスを入力してください

電話番号

* 内容 お問い合わせ内容をご入力ください

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%